The Difference of Bone Turnover Marker between Diabetes and Non-diabetes Osteoporotic Hip Fracture Patient

Authors

  • Pariwat Patphai Lerdsin Hospital
  • Thitinun Anusornvongchai Lerdsin Hospital

Keywords:

Bone remodeling, fragility hip fracture, Diabetes mellitus, Procollagen type 1 amino-terminal propeptide (P1NP), C-terminal of collagen (CTX)

Abstract

Background: Abnormal bone remodeling process (formation and resorption) results in osteoporosis, weakens bones and increases risk of fracture. Many medical diseases are associated with abnormal bone remodeling, such as chronic kidney disease, liver disease, cancer, and diabetes mellitus. Currently, laboratory evaluation of bone formation and bone resorption markers are available. Objective: To study the difference between these bone turnover markers in patients with fragility hip fracture who have diabetes mellitus, compared to non-diabetic patients. Methods: We conducted an analytical cross-sectional study in patients age 50 years or older who presented with fragility hip fracture and were admitted in Lerdsin Hospital from 1 February 2021 to 31 January 2022. Baseline demographic data, basic laboratory results (hemoglobin A1c, calcium, phosphate, vitamin D), bone formation marker (Procollagen type 1 amino-terminal propeptide; P1NP) levels, and bone resorption marker (C-terminal of collagen; CTX) levels were collected and further statistically analyzed with SPSS program. Result: A total of 109 patients were included in this study. There were 52 patients with diabetes (47.71%) and 57 non-diabetic patients (52.29%). The mean P1NP levels were 63.93 ng/mL in diabetes group and 53.24 ng/mL in non-diabetes (p-value = .483). The mean CTX levels were not significantly different between diabetic and non-diabetic patients, measuring 0.54 and 0.57 ng/mL, respectively (p-value = .326). However, diabetic patients tended to have a lower age at index fracture event, with a mean of 74.94 years, compared to 77.25 years in non-diabetic patients (p-value = .130). Conclusion: There was no statistically significant difference between serum levels of bone turnover markers, measured as P1NP for bone formation and CTX as bone resorption biomarkers, between diabetic and non-diabetic patients who had fragility hip fracture.

References

de Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 2005; 16(12):1713-20.

Valderrábano RJ, Linares MI. Diabetes mellitus and bone health: epidemiology, etiology and implications for fracture risk stratification. Clin Diabetes Endocrinol 2018;4:9.

Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocrinol Metab 2006;91(9):3404-10.

Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care 2006;29(7):1573-8.

Kulkarni SV, Meenatchi S, Reeta R, Ramesh R, Srinivasan AR, Lenin C. Association of glycemic status with bone turnover markers in type 2 diabetes mellitus. Int J Appl Basic Med Res 2017;7(4):247-51.

Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. Mechanisms in endocrinology: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017;176(3):R137-57.

Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22(2):391-420.

Songpatanasilp T, Sritara C, Kittisomprayoonkul W, Chaiumnuay S, Nimitphong H, Charatcharoenwitthaya N, et al. Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. Osteoporos Sarcopenia 2016;2(4):191-207.

Wang L, Li T, Liu J, Wu X, Wang H, Li X, et al. Association between glycosylated hemoglobin A1c and bone biochemical markers in type 2 diabetic postmenopausal women: a cross-sectional study. BMC Endocr Disord 2019;19(1):31.

Diabetes Association of Thailand under The Patronage of Her Royal Highness Princess Maha Chakri Sirindhorn. Clinical Practice Guideline for Diabetes 2017. Pathumthani: Romyen; 2018. p. 29-30.

Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996;28(12):1297-310.

Furst JR, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, et al. Advanced glycation endproducts and bone material strength in type 2 diabetes. J Clin Endocrinol Metab 2016;101(6):2502-10.

Li CI, Liu CS, Lin WY, Meng NH, Chen CC, Yang SY, et al. Glycated hemoglobin level and risk of hip fracture in older people with type 2 diabetes: a competing risk analysis of Taiwan diabetes cohort study. J Bone Miner Res 2015;30(7):1338-46.

Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005;289(5):E735-45.

Wittrant Y, Gorin Y, Woodruff K, Horn D, Abboud HE, Mohan S, et al. High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 2008;42(6):1122-30.

Downloads

Published

15-12-2023

How to Cite

1.
Patphai P, Anusornvongchai T. The Difference of Bone Turnover Marker between Diabetes and Non-diabetes Osteoporotic Hip Fracture Patient. J DMS [Internet]. 2023 Dec. 15 [cited 2024 Apr. 15];48(4):108-15. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/257327

Issue

Section

Original Article